Document is current

Any future updates will be listed below

Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Crossref DOI link: https://doi.org/10.1007/s00467-020-04874-z

Published Online: 2020-12-09

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark